Analyst Price Targets — DCTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 6:15 pm | — | Evercore ISI | $27.00 | $9.17 | StreetInsider | Delcath Systems (DCTH) PT Lowered to $27 at Clear Street |
| February 26, 2026 4:54 pm | Marie Thibault | BTIG | $19.00 | $9.17 | StreetInsider | Delcath Systems (DCTH) PT Lowered to $19 at BTIG |
| October 21, 2025 1:03 pm | Chase Knickerbocker | Craig-Hallum | $20.00 | $11.42 | TheFly | Delcath Systems price target lowered to $20 from $24 at Craig-Hallum |
| October 20, 2025 2:12 pm | — | H.C. Wainwright | $30.00 | $10.97 | TheFly | Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright |
| March 7, 2025 11:11 am | — | H.C. Wainwright | $24.00 | $13.00 | TheFly | Delcath Systems price target raised to $24 from $22 at H.C. Wainwright |
| May 15, 2024 7:22 am | Swayampakula Ramakanth | H.C. Wainwright | $22.00 | $7.54 | StreetInsider | Delcath Systems (DCTH) PT Raised to $22 at H.C. Wainwright |
Latest News for DCTH
Delcath Systems (NASDAQ: DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-center capacity, increasing new patient starts, and strengthening referral networks. On the company's fourth-quarter and year-end 2025 earnings call, executives also provided 2026 revenue guidance of at least $100 million…
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year…
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial…
Micron Solutions (OTCMKTS:MICR - Get Free Report) and Delcath Systems (NASDAQ: DCTH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk. Valuation and Earnings This table compares Micron
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DCTH.
U.S. House Trading
No House trades found for DCTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.